Prof. Nagler completed his medical studies at the Hebrew University – Hadassah Medical School, followed by an internal medicine residency and hematology fellowship at Rambam Medical Center. He then obtained a Master’s Degree in hematopoiesis from Tel Aviv University before moving to the US to complete his postdoctoral research fellowship in hematology and bone marrow transplantation at Stanford University Hospital.

A pioneer of non-myeloablative and reduced intensity\toxicity allogeneic transplantations for both malignant and non-malignant tumors, Prof. Nagler has published hundreds of articles, reviews, and chapters in premier peer-reviewed journals, and is the principal investigator of multiple clinical studies, while also holding several patents.

At present, Prof. Nagler serves as President of the Hemato-Oncology Center
at Sheba Medical Center, and is also a Professor of Medicine at Tel Aviv University. Concurrently, Prof. Nagler is an active member of the European Group for Blood and Marrow Transplantation (EBMT), sits on the International NetCord Foundation’s board of directors, serves on the editorial board of several journals, and is the Stem Cell Transplantation Section Editor for the Leukemia scientific journal.

During the past few years, Prof. Nagler’s work has involved investigating strategies to improve outcomes after hematopoietic stem cell transplantation (HSCT) and developing novel treatment strategies for hematological malignancies. His recent work has been on the use of reduced-intensity conditioning before HSCT in patients with secondary acute myeloid leukemia (AML). Moreover, he recently participated in a study investigating the safety and efficacy of a CD19/CD22 dual-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory aggressive B-cell lymphoma.